戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 ated, S-6 fraction demonstrated highest anti-trypanosomal activity at 2.4 ug/ml MIC followed by fiset
2 inidol at 4.7 ug/ml reflecting that the anti-trypanosomal activity is attributable to the presence of
3                                     The anti-trypanosomal activity of the extracts was linked to the
4 al least squares (PLS) modelling of the anti-trypanosomal activity of the sample extracts using the L
5 mura and co-workers that exhibit modest anti-trypanosomal activity.
6 f the trypanosomal glycerol kinase (TGK) and trypanosomal alternative oxidase (TAO) is considered a v
7 36 but does not require Sam50 or ATOM40, the trypanosomal analogue of the Tom40 import pore.
8 ve of the role of propolis as potential anti-trypanosomal and anticancer agent for effective cancer t
9 y and selectively inhibit TbcatB relative to trypanosomal and human homologues.
10 ls are first line drugs for the treatment of trypanosomal and leishmanial diseases.
11 hat caused markedly pronounced inhibition of trypanosomal and neoplastic cell growth and viability.
12 the uncleaved maturation intermediate from a trypanosomal cathepsin L-like protease is currently not
13                                          The trypanosomal cathepsin TbcatB is essential for parasite
14 ved pH sensitivity of proenzyme cleavage in (trypanosomal) CathL-like proteases.
15 lycerol, is an inhibitor of this enzyme in a trypanosomal cell-free system.
16 gical target for the development of new anti-trypanosomal chemotherapy.
17 used by the intracellular protozoan parasite Trypanosomal cruzi , and current drugs are lacking in te
18 hat VNI, a potent and selective inhibitor of trypanosomal CYP51 that we identified and structurally c
19  antitrypanosomal activity via inhibition of trypanosomal cysteine proteases, TbCatB and rhodesain, t
20  evaluation of inhibitors of leishmanial and trypanosomal dihydrofolate reductase.
21  toward using 1 as a starting point for anti-trypanosomal drug discovery, we report efforts to reduce
22 on of trypanothione biosynthesis by the anti-trypanosomal drug Eflornithine impairs the ability of th
23 ibition in thiamine uptake, whereas the anti-trypanosomal drug, melarsoprol, failed to affect the upt
24 current priority given that several new anti-trypanosomal drugs, with known targets, are currently in
25 ggest that it could be a new target for anti-trypanosomal drugs.
26  "drug repurposing" approach, we tested anti-trypanosomal effects of carbazole-derived compounds call
27 uggest that these compounds exert their anti-trypanosomal effects, at least in part, by inhibition of
28 , influence on the catalytic activity of the trypanosomal enzyme and its human counterpart, and their
29 or S109L), as the homologous residues in the trypanosomal enzyme contribute to the previously unrecog
30                       We also show that this trypanosomal enzyme is inhibited by known inhibitors of
31                 Our characterization of this trypanosomal enzyme shows that it is possible to disting
32 h plasmodial helix 18, and Tc-18Hs-SAHH, the trypanosomal enzyme with human helix 18.
33 wn herein to be a selective inhibitor of the trypanosomal enzyme.
34 cellular retention confirming that MDDL is a trypanosomal ER localization signal.
35               Simultaneous inhibition of the trypanosomal glycerol kinase (TGK) and trypanosomal alte
36 cNAc-PI) is the second step of mammalian and trypanosomal glycosylphosphatidylinositol biosynthesis.
37 e formation of ICLs leading to inhibition of trypanosomal growth.
38          Hs-18Tc-SAHH, the human enzyme with trypanosomal helix 18, was also prepared but differed in
39   This protease may be related to TbMSP-B, a trypanosomal homologue of Leishmania major surface prote
40 f T. cruzi or a parasite-conditioned medium (trypanosomal immunosuppressive factor (TIF) to cultures
41  in Africa because they confer resistance to trypanosomal infection and protect from African sleeping
42 hagas' disease, become highly susceptible to trypanosomal infection.
43 ent first total synthesis of the potent anti-trypanosomal macrolide (+)-actinoallolide A has been ach
44                            Expression of the trypanosomal mitochondrial genome requires the insertion
45 g cascade to generate open reading frames in trypanosomal mitochondrial mRNAs.
46                              The majority of trypanosomal mitochondrial pre-mRNAs undergo massive uri
47 ed by a polyclonal antibody made against the trypanosomal mitochondrial topo II enzyme.
48                           The structure of a trypanosomal N-ribohydrolase in complex with a transitio
49 llular compartments in T. cruzi using either trypanosomal or mammalian signal sequences.
50      However, TAC40 does not colocalize with trypanosomal orthologs of ERMES components and, unlike M
51  pATOM36, a novel essential component of the trypanosomal outer membrane protein import system that i
52          So far, the ChaC family proteins in trypanosomal parasites are missing in the literature.
53 date, the nonglycolytic function of GAPDH in trypanosomal parasites is absent from the literature.
54 ing a (13)C-labelled metabolome dataset from trypanosomal parasites.
55 ate immune response, and the pathobiology of trypanosomal parasites.
56 edge the first pharmacological validation of trypanosomal PDEs as drug targets.
57 rmacologically validate the highly conserved trypanosomal PDEs as potential drug targets.
58                                              Trypanosomal phosphodiesterases B1 and B2 (TbrPDEB1 and
59                                          The trypanosomal prodomain differs from nonparasitic pro-cat
60  of aristeromycin, possessed meaningful anti-trypanosomal properties has prompted a search of other 7
61 sess the highest binding affinity toward the trypanosomal protease (K(i) = 0.6 pM) and a submicromola
62 growth, restored import of a large subset of trypanosomal proteins that lack TMDs.
63 7-deazapurines with similar or improved anti-trypanosomal responses.
64 ial cofactor binding properties of human and trypanosomal SAHHs (Hs-SAHH and Tc-SAHH), within 5 A of
65  well as advances in the characterization of trypanosomal secretory machinery, provide a unique model
66 is the first characterization of a UP from a trypanosomal source despite this activity being observed
67            Excellent in vivo activity in the trypanosomal STIB900 mouse model was found for five of t
68        Comparison of apo and histidine-bound trypanosomal structures indicates substantial active-sit
69 ouple occupies a central position within the trypanosomal thiol metabolism and delivers electrons als
70 hrough selective, irreversible inhibition of trypanosomal topoisomerase II by stabilizing double-stra
71  protein and identifies tSNAP(c) as a unique trypanosomal transcription factor.
72 cation of hitherto unknown m(1)A residues in trypanosomal tRNA.
73 f the UTP-bound and apo forms of the minimal trypanosomal TUTase, TbTUT4, which is composed solely of
74 ructural and biochemical analyses of a novel trypanosomal TUTase, TbTUT4, which represents a minimal
75 Furthermore, substantial differences between trypanosomal TyrRS and human homologs are promising for